← Back to All US Stocks

Dyadic International Inc. (DYAI) Stock Fundamental Analysis & AI Rating 2026

DYAI Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001213809
Updated This Month • Analysis: Mar 23, 2026 • SEC Data: 2025-09-30
Combined AI Rating
SELL
87% Confidence
AGREEMENT
STRONG SELL
92% Conf
SELL
82% Conf

📊 DYAI Key Takeaways

Revenue: $2.5M
Net Margin: -229.6%
Free Cash Flow: $-3.9M
Current Ratio: 2.85x
Debt/Equity: 0.00x
EPS: $-0.17
AI Rating: STRONG SELL with 92% confidence
Dyadic International Inc. (DYAI) receives a SELL rating with 87% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $2.5M, net profit margin of -229.6%, and return on equity (ROE) of -222.3%, Dyadic International Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete DYAI stock analysis for 2026.

Is Dyadic International Inc. (DYAI) a Good Investment?

Claude

Dyadic International is a pre-revenue biotech company experiencing severe financial distress with massive operating losses (-224% margin) despite minimal revenue generation ($2.5M). Negative operating and free cash flows (-$3.9M) combined with a narrow equity cushion ($2.6M) create existential runway concerns, making this a high-risk speculative position unsuitable for fundamental analysis.

ChatGPT

DYADIC INTERNATIONAL shows some top-line momentum, but the growth quality is weak because revenue remains very small relative to its cost base and losses are extreme. Operating and net margins are deeply negative, operating cash flow is materially negative, and the company is consuming cash rather than converting revenue into sustainable earnings. The balance sheet benefits from solid near-term liquidity and no meaningful debt, but the low equity base leaves limited room for prolonged underperformance.

Why Buy Dyadic International Inc. Stock? DYAI Key Strengths

Claude
  • + Adequate liquidity position with $5.8M cash and 2.85x current ratio providing near-term operational runway
  • + Zero long-term debt eliminating refinancing risk
  • + Revenue growth of 20.6% YoY indicating early commercial traction in biological products
ChatGPT
  • + Revenue grew 20.6% year over year, indicating some commercial traction
  • + Cash of $5.83M and current/quick ratios of 2.85x support near-term liquidity
  • + No meaningful debt reduces financial leverage risk

DYAI Stock Risks: Dyadic International Inc. Investment Risks

Claude
  • ! Severe operating losses of -$5.7M on $2.5M revenue indicates unsustainable unit economics and business model viability concerns
  • ! Negative free cash flow of -$3.9M will deplete $5.8M cash reserves within 18 months without revenue acceleration or cost restructuring
  • ! Stockholders equity of only $2.6M provides minimal financial cushion; continued losses will rapidly erode shareholder value
  • ! Persistent negative profitability across all margins (-224% operating, -230% net) indicates fundamental business challenges not temporary setbacks
ChatGPT
  • ! Operating margin of -224.1% and net margin of -229.6% show an unsustainable cost structure
  • ! Negative operating cash flow and free cash flow of $-3.93M indicate ongoing cash burn
  • ! Stockholders' equity of only $2.61M creates a thin capital buffer if losses continue

Key Metrics to Watch

Claude
  • * Quarterly revenue trajectory and gross margin achievement as commercial partnerships scale
  • * Operating cash burn rate and cash runway extension timeline
  • * Progress toward breakeven on operating basis and path to sustainable unit economics
ChatGPT
  • * Operating cash burn relative to cash balance
  • * Revenue growth versus operating expense growth

Dyadic International Inc. (DYAI) Financial Metrics & Key Ratios

Revenue
$2.5M
Net Income
$-5.8M
EPS (Diluted)
$-0.17
Free Cash Flow
$-3.9M
Total Assets
$11.7M
Cash Position
$5.8M

💡 AI Analyst Insight

Strong liquidity with a 2.85x current ratio provides a solid financial cushion.

DYAI Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -224.1%
Net Margin -229.6%
ROE -222.3%
ROA -49.7%
FCF Margin -155.7%

DYAI vs Healthcare Sector: How Dyadic International Inc. Compares

How Dyadic International Inc. compares to Healthcare sector averages

Net Margin
DYAI -229.6%
vs
Sector Avg 12.0%
DYAI Sector
ROE
DYAI -222.3%
vs
Sector Avg 15.0%
DYAI Sector
Current Ratio
DYAI 2.8x
vs
Sector Avg 2.0x
DYAI Sector
Debt/Equity
DYAI 0.0x
vs
Sector Avg 0.6x
DYAI Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Dyadic International Inc. Stock Overvalued? DYAI Valuation Analysis 2026

Based on fundamental analysis, Dyadic International Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-222.3%
Sector avg: 15%
Net Profit Margin
-229.6%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Dyadic International Inc. Balance Sheet: DYAI Debt, Cash & Liquidity

Current Ratio
2.85x
Quick Ratio
2.85x
Debt/Equity
0.00x
Debt/Assets
77.7%
Interest Coverage
N/A
Long-term Debt
N/A

DYAI Revenue & Earnings Growth: 5-Year Financial Trend

DYAI 5-year financial data: Year 2021: Revenue $2.4M, Net Income -$9.3M, EPS N/A. Year 2022: Revenue $2.9M, Net Income -$13.1M, EPS N/A. Year 2023: Revenue $2.9M, Net Income -$9.7M, EPS N/A. Year 2024: Revenue $3.5M, Net Income -$6.8M, EPS N/A. Year 2025: Revenue $3.5M, Net Income -$5.8M, EPS $-0.20.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Dyadic International Inc.'s revenue has grown significantly by 45% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.20 indicates the company is currently unprofitable.

DYAI Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-155.7%
Free cash flow / Revenue

DYAI Quarterly Earnings & Performance

Quarterly financial performance data for Dyadic International Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $1.2M -$203.5K $-0.01
Q2 2025 $385.9K -$1.8M $-0.06
Q1 2025 $334.6K -$2.0M N/A
Q3 2024 $397.1K -$203.5K N/A
Q2 2024 $385.9K -$956.4K N/A
Q1 2024 $334.6K -$956.4K N/A
Q3 2023 $397.1K -$956.4K N/A
Q2 2023 $658.6K -$956.4K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Dyadic International Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$3.9M
Cash generated from operations
Dividends
None
No dividend program

DYAI SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Dyadic International Inc. (CIK: 0001213809)

📋 Recent SEC Filings

Date Form Document Action
Mar 30, 2026 8-K form8-k.htm View →
Mar 25, 2026 8-K form8-k.htm View →
Mar 25, 2026 10-K form10-k.htm View →
Mar 6, 2026 8-K form8-k.htm View →
Jan 6, 2026 4 xslF345X05/ownership.xml View →

Frequently Asked Questions about DYAI

What is the AI rating for DYAI?

Dyadic International Inc. (DYAI) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are DYAI's key strengths?

Claude: Adequate liquidity position with $5.8M cash and 2.85x current ratio providing near-term operational runway. Zero long-term debt eliminating refinancing risk. ChatGPT: Revenue grew 20.6% year over year, indicating some commercial traction. Cash of $5.83M and current/quick ratios of 2.85x support near-term liquidity.

What are the risks of investing in DYAI?

Claude: Severe operating losses of -$5.7M on $2.5M revenue indicates unsustainable unit economics and business model viability concerns. Negative free cash flow of -$3.9M will deplete $5.8M cash reserves within 18 months without revenue acceleration or cost restructuring. ChatGPT: Operating margin of -224.1% and net margin of -229.6% show an unsustainable cost structure. Negative operating cash flow and free cash flow of $-3.93M indicate ongoing cash burn.

What is DYAI's revenue and growth?

Dyadic International Inc. reported revenue of $2.5M.

Does DYAI pay dividends?

Dyadic International Inc. does not currently pay dividends.

Where can I find DYAI SEC filings?

Official SEC filings for Dyadic International Inc. (CIK: 0001213809) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is DYAI's EPS?

Dyadic International Inc. has a diluted EPS of $-0.17.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is DYAI a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Dyadic International Inc. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is DYAI stock overvalued or undervalued?

Valuation metrics for DYAI: ROE of -222.3% (sector avg: 15%), net margin of -229.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy DYAI stock in 2026?

Our dual AI analysis gives Dyadic International Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is DYAI's free cash flow?

Dyadic International Inc.'s operating cash flow is $-3.9M, with capital expenditures of N/A. FCF margin is -155.7%.

How does DYAI compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -229.6% (avg: 12%), ROE -222.3% (avg: 15%), current ratio 2.85 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2025-09-30 | Powered by Claude AI